株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

糖尿病性胃アトニー : パイプライン製品の分析

Diabetic Gastroparesis - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 229780
出版日 ページ情報 英文 56 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.21円で換算しております。
Back to Top
糖尿病性胃アトニー : パイプライン製品の分析 Diabetic Gastroparesis - Pipeline Review, H2 2017
出版日: 2017年08月16日 ページ情報: 英文 56 Pages
概要

胃アトニーとは、糖尿病の長期的な合併症の一つで、胃の消化機能に悪影響を及ぼします。高血糖が持続的に続くことにより、人体各所の神経、特に迷走神経(消化時の胃の収縮活動を制御する神経)が侵されます。発症すると、痙攣や腹痛、少し食べただけでも満腹感を感じる、吐き気・嘔吐、胃逆流、胸焼け、膨満感といった症状が生じます。さらには、食欲不振や栄養摂取量の減少も生じ、それが体重減少や栄養失調につながります。

当レポートでは、世界各国での糖尿病性胃アトニー治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

糖尿病性胃アトニーの概要

治療薬の開発

  • 糖尿病性胃アトニー向けパイプライン製品:概要
  • 糖尿病性胃アトニー向けパイプライン製品:比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

企業で開発中の製品

大学/機関で開発中の製品

糖尿病性胃アトニー治療薬の開発に従事している企業

  • Cempra Inc
  • Evoke Pharma, Inc.
  • GlaxoSmithKline Plc
  • Motus Therapeutics Inc
  • Shire Plc
  • Theravance Biopharma, Inc.

糖尿病性胃アトニー:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

糖尿病性胃アトニー治療薬:開発が休止状態の製品

糖尿病性胃アトニー治療薬:開発が中止された製品

糖尿病性胃アトニー関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9631IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Gastroparesis - Pipeline Review, H2 2017, provides an overview of the Diabetic Gastroparesis (Gastrointestinal) pipeline landscape.

Gastroparesis is a long-term complication of diabetes that involves the stomach and affects digestion. Prolonged high blood sugar levels can damage nerves in many parts of the body, including the vagus nerve, which controls contractions of the stomach during digestion. Spasms, abdominal pain, feelings of fullness after a small amount of food, and other symptoms such as nausea and vomiting, reflux, heartburn, and bloating are often experienced with gastroparesis. Loss of appetite and reduced absorption of nutrients may also be experienced. Gastroparesis can lead to weight loss and malnutrition.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Gastroparesis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Diabetic Gastroparesis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Gastroparesis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Gastroparesis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 3, 1 and 2 respectively.

Diabetic Gastroparesis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Gastroparesis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Gastroparesis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Gastroparesis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Gastroparesis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Gastroparesis (Gastrointestinal)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Gastroparesis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Gastroparesis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Diabetic Gastroparesis - Overview
    • Diabetic Gastroparesis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Diabetic Gastroparesis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Diabetic Gastroparesis - Companies Involved in Therapeutics Development
    • Allergan Plc
    • Cempra Inc
    • Evoke Pharma Inc
    • GlaxoSmithKline Plc
    • Johnson & Johnson
    • Theravance Biopharma Inc
  • Diabetic Gastroparesis - Drug Profiles
    • camicinal - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CEM-031 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ETX-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ETX-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • metoclopramide hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • prucalopride succinate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • relamorelin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • renzapride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • velusetrag hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Diabetic Gastroparesis - Dormant Projects
  • Diabetic Gastroparesis - Discontinued Products
  • Diabetic Gastroparesis - Product Development Milestones
    • Featured News & Press Releases
      • Aug 09, 2017: EndoLogic Announces Feedback from Positive FDA Meeting for Renzapride in Diabetic Gastroparesis
      • May 31, 2017: Evoke Pharma Enters Agreement with Rho to Submit NDA for Gimoti
      • May 15, 2017: Evoke Pharma Provides Update on Gimoti
      • May 10, 2017: Evoke Pharma Presents Gimoti Efficacy and Safety Data from Phase 3 Trial as Late Breaker at Digestive Disease Week 2017
      • May 03, 2017: EndoLogic Announces Scheduling of pre-IND Meeting with FDA to Discuss Renzapride in Diabetic Gastroparesis
      • May 01, 2017: Allergan to Present Data on Relamorelin at Digestive Disease Week 2017
      • Apr 04, 2017: Positive Type A Meeting with FDA Confirms Acceptability of Evoke Pharma's Proposed Comparative Exposure PK Trial for Gimoti NDA
      • Mar 21, 2017: Evoke Pharmas Phase 3 Results for Gimoti Accepted as Late-Breaker for Presentation at Digestive Disease Week 2017
      • Jan 04, 2017: Evoke Provides Additional Data Demonstrating Statistically Significant Benefit for Gimoti in Moderate to Severe Patients in Phase 3 Diabetic Gastroparesis Trial
      • Dec 15, 2016: Evoke Receives Positive NDA Submission Guidance from US FDA for Gimoti
      • Dec 06, 2016: Theravance Biopharma Receives FDA Fast Track Designation for Velusetrag (TD-5108) for Idiopathic and Diabetic Gastroparesis
      • Sep 07, 2016: Evoke Pharma Announces Positive Non-Clinical Pre-NDA Meeting with FDA for Gimoti
      • Jul 26, 2016: Evoke Pharma Receives Conditional FDA Acceptance of Proposed Brand Name for EVK-001
      • Jul 18, 2016: Evoke Pharma Reports Topline Results from EVK-001 Phase 3 Clinical Trial
      • Jul 07, 2016: Evoke Advances Commercial Preparations for EVK-001 with inVentiv Agreement
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Diabetic Gastroparesis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Diabetic Gastroparesis - Pipeline by Allergan Plc, H2 2017
  • Diabetic Gastroparesis - Pipeline by Cempra Inc, H2 2017
  • Diabetic Gastroparesis - Pipeline by Evoke Pharma Inc, H2 2017
  • Diabetic Gastroparesis - Pipeline by GlaxoSmithKline Plc, H2 2017
  • Diabetic Gastroparesis - Pipeline by Johnson & Johnson, H2 2017
  • Diabetic Gastroparesis - Pipeline by Theravance Biopharma Inc, H2 2017
  • Diabetic Gastroparesis - Dormant Projects, H2 2017
  • Diabetic Gastroparesis - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Diabetic Gastroparesis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top